NEW YORK, Dec. 6, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced that the company is providing an update on its technology platform advancements and pipeline of ZFP Therapeutics ® as well as near- and mid-term operating goals during an Analyst and Investor Briefing being held today in New York City. The presentation, by members of Sangamo management team, will be webcast live beginning at 5:00 pm ET and can be accessed via a link on the Company's website.
"We are very excited to share the progress that we have made in advancing our zinc finger DNA binding protein (ZFP) technology and ZFP Therapeutic programs, particularly in the area of monogenic diseases where we have developed a new, highly disruptive therapeutic platform for protein replacement therapies," said Edward Lanphier, president and CEO of Sangamo. "This approach can be leveraged across multiple diseases with the goal of engineering genetic cures."
"Sangamo's proprietary gene-editing and gene-regulation technology is unique in its ability to generate novel, highly differentiated therapies that act at the DNA-level," stated Geoff Nichol, M.B., Ch.B ., Sangamo's executive vice president of research and development. "This capability enables us to address the source of a wide variety of genetic diseases and potentially cure them. In addition to two ongoing Phase 2 clinical trials of SB-728-T, which may afford a functional cure for HIV/AIDS, we have a rich pipeline of preclinical programs. These include ZFP Therapeutics for hemophilia and Huntington's disease, which we are developing in collaboration with Shire, as well as Sangamo's programs in hemoglobinopathies (sickle cell disease and beta-thalassemia) and lysosomal storage diseases (LSDs). Based upon our ZFP Therapeutic approach and the disease targets that we have selected, we expect to file up to seven new INDs by 2015.""Commercially, our business model has enabled us to monetize the value of our ZFP technology platform and maintain a strong balance sheet through partnerships with Dow AgroSciences in plant agriculture and Sigma-Aldrich Corporation in life science research reagents, while making significant progress in advancing our ZFP Therapeutics programs," continued Mr. Lanphier. "Beyond our very significant collaboration with Shire, we plan to establish additional high-value strategic partnerships around selected therapeutic programs at points of realizable value inflection while continuing to advance proprietary programs and increasingly forward integrate."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV